{"schema_version":"secwatch.filing_event.v1","accession":"0001401914-26-000032","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2026-06-12T20:01:09+00:00","discovered_at":"2026-06-12T20:01:32.053304+00:00","generated_at":"2026-06-12T20:01:48.098645+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Daré Bioscience stockholders approve 1.5M share increase in 2022 plan and ratify auditor","bullets":["Stockholders approved amendment to 2022 Stock Incentive Plan adding 1,500,000 shares; total reserve becomes 2,883,333 shares.","Elected directors Gregory W. Matz (3,752,211 votes for) and Sabrina Martucci Johnson (3,848,085 votes for).","Ratified Haskell & White LLP as independent auditor for FY2026 (7,754,883 votes for).","Approved potential future issuances under Lincoln Park Capital equity line (3,771,709 votes for).","Say-on-pay approved (3,625,596 votes for); board set advisory vote frequency at every year."],"urls":{"canonical":"https://secwatch.observer/filing/0001401914-26-000032","json":"https://secwatch.observer/filing/0001401914-26-000032.json","markdown":"https://secwatch.observer/filing/0001401914-26-000032.md","text":"https://secwatch.observer/filing/0001401914-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/dare-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:01:48.098645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0553e6d6da0a4546cbc44c6d8040f3df8de6b62b","claim":"Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 5 if necessary at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 7 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 5 if there were not sufficient votes to approve Proposal 5 by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"17b4b90f00d8a0207641a7fa9e2e3b992b965dfe","claim":"Dare Bioscience, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 3 : Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"323ea7a0e29cb45b380553d8b9c82e734f4ba257","claim":"Dare Bioscience, Inc. shareholders approved Approval of potential future issuance of shares under equity line with Lincoln Park Capital Fund, LLC (Nasdaq rule) at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 5 : Our stockholders approved, in accordance with Nasdaq rules, the potential future issuance of shares of our common stock under our existing equity line with Lincoln Park Capital Fund, LLC by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"6889d72f0d3799bf716193eea984d149b6c1f21d","claim":"Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 6 if necessary at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 8 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there were not sufficient votes to approve Proposal 6 by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"68915052cafbbc9afeb1a28f4e2c8cb2ef549aa0","claim":"Dare Bioscience, Inc. shareholders approved Approval of amendment to 2022 Stock Incentive Plan to increase shares available by 1,500,000 at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 6 : Our stockholders approved the 2022 Plan Amendment by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"6ec16367252b639e75ac308b012621b5a95a69a8","claim":"Dare Bioscience, Inc. shareholders approved Advisory vote on preferred frequency of holding advisory vote on executive compensation at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 4 : Our stockholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of our named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"cbb03ee3e3d0cf8f293dfa141594ed52aab3f009","claim":"Dare Bioscience, Inc. shareholders approved Election of Class III directors at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 1 : Each of the director nominees identified in the table below was elected as a Class III director to hold office until our 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"d9f3a4a06aebfea8c0036b7a935ae46d55c50869","claim":"Dare Bioscience, Inc. shareholders approved Ratification of appointment of Haskell & White LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"Proposal 2 : Our stockholders ratified the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/0001401914-26-000032-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}